Kospi reclaims 2,700 intraday amid preelection momentum
The Kospi opened strong at 2,709.92, nearly 10 points above Friday's close, and climbed to an early high of 2,719.87 within the first 20 minutes. The index remained above 2,700 through the morning before paring gains to end slightly higher at 2,698.97.
While slightly weaker than last week's momentum, Monday's performance marked a continuation of the recent rally. The Kospi had broken above 2,700 last Wednesday for the first time in nine months, after months of trading between 2,400 and the mid-2,600s and stalling near 2,600 in May.
Institutional investors weighed on the market, emerging as net sellers of roughly 241.5 billion won ($175.8 million). Foreign investors flipped the Kospi into positive territory late in the session, ramping up purchases to end as the day's biggest buyers with a net 125.1 billion won. Retail investors also helped support the index, adding 99 billion won in net purchases.
The secondary Kosdaq showed a contrasting trend, climbing around 0.8 percent to close at 740.29. Unlike the Kospi, retail investors turned net sellers, offloading roughly 120 billion won, while foreign and institutional investors stepped in as net buyers, purchasing 111.7 billion won and 14.3 billion won, respectively.
'With the Kospi awaiting the outcome of Tuesday's presidential election, the market is heading into the holiday without a clear directional catalyst,' said Lee Jae-won, analyst at Shinhan Securities.
Sector performance was mixed, with no clear trend across industries. Chipmakers such as Samsung Electronics and SK hynix posted modest gains, while Hyundai Heavy Industries and Hanwha Aerospace also stood out among heavyweight advancers. In contrast, financial stocks, which had rallied last week, surrendered part of their recent gains.
Meanwhile, the Korean won weakened about 0.7 percent to trade near 1,374 won per US dollar as of 4 p.m. Monday.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Korea Herald
4 hours ago
- Korea Herald
Lee, Turkish president agree to strengthen strategic partnership
President Lee Jae Myung and Turkish President Recep Tayyip Erdogan on Thursday agreed to further strengthen the strategic partnership between the two countries, the presidential office said. In the phone call, the two leaders assessed the close economic cooperation in areas such as trade and investment, and pledged to further expand practical collaboration in defense, arms, nuclear energy and green energy, presidential spokesperson Kang Yu-jung said in a written briefing. "I am pleased that our two countries have continued to develop relations based on the historic bond formed during the Korean War," Lee was quoted as saying. The Turkish leader congratulated Lee on taking office and paid tribute to the restoration of democracy in South Korea and the resilience of the Korean people, Kang added. (Yonhap)
Korea Herald
7 hours ago
- Korea Herald
Seoul shares end higher on auto, shipbuilding gains
Seoul shares closed higher Thursday supported by advances in auto and shipbuilding stocks, despite lingering investor concerns over US tariff policies. The Korean won fell against the US dollar. The benchmark Korea Composite Stock Price Index rose 5.91 points, or 0.19 percent, to close at 3,192.29. Trade volume was moderate at 416.29 million shares worth 14.95 trillion won (US$10.7 billion). Decliners outnumbered gainers 470 to 390. Institutions and foreigners bought a net 159.84 billion won and 50.13 billion won worth of stocks, respectively, while individuals sold a net 335.64 billion won. "Lingering concerns over (US President Donald) Trump's tariffs weighed on sentiment, and profit-taking in SK hynix limited gains in the main index," Lee Jae-won, an analyst at Shinhan Securities Co., said. Trump recently notified key US trading partners, including South Korea, of new reciprocal tariffs set to take effect Aug. 1 unless they negotiate better trade terms with Washington. In Seoul, large-cap stocks closed mixed. Market bellwether Samsung Electronics jumped 3.09 percent to 66,700 won, while chip giant SK hynix plunged 8.95 percent to 269,500 won. On Thursday, the Supreme Court upheld the acquittal of Samsung Electronics Chairman Lee Jae-yong, affirming lower court rulings that cleared him of financial crimes related to a 2015 merger between Samsung affiliates that consolidated his control over the conglomerate. Meanwhile, SK hynix tumbled after Goldman Sachs downgraded the chipmaker to neutral from buy, citing a possible decline in high-bandwidth memory prices next year amid intensifying competition. Top carmaker Hyundai Motor rose 1.2 percent to 210,000 won, while major shipbuilder Hanwha Ocean climbed 3.46 percent to 80,700 won. Leading battery maker LG Energy Solution gained 1.93 percent to 317,000 won, and cosmetics giant Amorepacific added 2 percent to 137,700 won. Among decliners, leading refiner SK Innovation fell 0.45 percent to 111,600 won, and Lotte Shopping slipped 0.26 percent to 75,900 won. The local currency was quoted at 1,392.60 won against the greenback at 3:30 p.m., down 6.9 won from the previous session. (Yonhap)
Korea Herald
8 hours ago
- Korea Herald
GC Biopharma Receives Marketing Authorization for BARYCELA in Vietnam
YONGIN, South Korea, July 17, 2025 /PRNewswire/ -- GC Biopharma ( a South Korean pharmaceutical company, announced that its varicella vaccine BARYCELA has received marketing authorization from the Drug Administration of Vietnam (DAV). Following domestic approval in 2020 and WHO Pre-Qualification (PQ) in 2023, GC Biopharma has been accelerating individual country registrations as part of its dual-track strategy—pursuing both global procurement channels and direct market entry initiatives. To obtain approval in Vietnam, GC Biopharma conducted local clinical trials to establish the product's safety and immunogenicity. This achievement highlights the company's ability to meet the increasingly stringent regulatory standards set by DAV. As a vaccine administered primarily to children, quality certification holds particular importance in the varicella segment. GC Biopharma plans to establish stable annual revenue in Vietnam by leveraging its local affiliate to engage directly in sales activities, in consideration of the country's private market-oriented vaccine distribution system. From 2018 to 2021, Vietnam's private vaccine market recorded a compound annual growth rate (CAGR) of 32%, reaching approximately USD 300 million in 2021. Varicella vaccines accounted for nearly 10% of the private market [1], with demand for private vaccinations continuing to grow steadily. "This marketing authorization represents more than a product export—it is the result of a localization strategy and a significant step toward expansion in Southeast Asia," said Jae Woo Lee, Head of Development Department at GC Biopharma. "We will continue to strengthen our position as a trusted vaccine brand by delivering clinical and quality standards that meet global expectations." BARYCELA is a live attenuated varicella vaccine developed by GC Biopharma using its proprietary MAV/06 virus strain. The vaccine is characterized by high viral titer and manufacturing yield. Notably, BARYCELA is the world's first varicella vaccine produced without antibiotics, utilizing a fully aseptic manufacturing process. About GC Biopharma GC Biopharma (formerly known as Green Cross Corporation) is a biopharmaceutical company headquartered in Yong-in, South Korea. The company has over half a century of experience in the development and manufacturing of plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo ® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D capabilities in engineering of proteins, mRNAs, and lipid nanoparticle (LNP) drug delivery platform to develop therapeutics for the field of rare disease as well as I&I (Immunology & Inflammation). To learn more about the company, visit This press release may contain biopharmaceuticals in forward-looking statements, which express the current beliefs and expectations of GC Biopharma's management. Such statements do not represent any guarantee by GC Biopharma or its management of future performance and involve known and unknown risks, uncertainties, and other factors. GC Biopharma undertakes no obligation to update or revise any forward-looking statement contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Sohee Kim Yelin Jun
